Nektar Therapeutics Soars on Takeover Rumors

Nektar Therapeutics shares rose 8% amid speculation of a potential takeover by Eli Lilly. The speculation is based on posts on social media and a report on CNBC, as covered in a a Seeking Alpha article. The exact nature of the speculation is unclear, but it has contributed to an increase in the company's stock price.

Nektar Therapeutics (NASDAQ: NKTR) saw its shares rise by 8% on September 12, 2025, amidst speculation of a potential acquisition by Eli Lilly (NYSE: LLY). The speculation, fueled by posts on social media and a report on CNBC, has contributed to a significant increase in the company's stock price. The exact nature of the speculation remains unclear, but the market's response has been notable.

Nektar Therapeutics has had a remarkable year, with its shares surging 294% through Thursday, September 12, 2025. The company's market capitalization currently stands at $1.05 billion, making it an attractive target for potential acquirers. Eli Lilly, with a market capitalization of $736 billion, is expected to report its Q3 results on October 30, 2025.

Eli Lilly has been in the news for its progress in various therapeutic areas, including diabetes and weight loss medications. Recent positive data from Eli Lilly's oral weight loss drug for diabetes has bolstered its value proposition. However, the company's stock has also been affected by regulatory decisions, such as the FDA voucher exclusion for orforglipron.

As the speculation around Nektar Therapeutics continues to develop, investors and financial professionals will closely monitor the situation. The potential acquisition could have significant implications for both companies, including strategic alignment, financial synergies, and market positioning.

For more information, see the Seeking Alpha article cited above.